Medtronic Awarded FDA Clearance for 2 AI Algorithms for Cardiac Monitoring

What You Should Know:

– Medtronic announced U.S. Food and Drug Administration (FDA) clearance for two AccuRhythm™ AI algorithms for use with the LINQ II™ insertable cardiac monitor (ICM) – and the presentation of AccuRhythm AI validation data this week at Heart Rhythm 2021.

– AccuRhythm AI applies artificial intelligence (AI) to heart rhythm event data collected by LINQ II, improving the accuracy of information physicians receive so they can better diagnose and treat abnormal heart rhythms.

The small, wireless LINQ II ICM is the world’s most accurate ICM,1-4 and the new cloud-based AccuRhythm AI algorithms further enhance LINQ II ICM’s delivery of accurate heart rhythm alerts. The algorithms address the two most common ICM false alerts – atrial fibrillation (AF), an irregular or rapid rhythm in the upper chambers of the heart; and asystole, a long pause between heartbeats. 5-6 Medtronic developed the AccuRhythm AI platform and initial algorithms using its proprietary, diverse and debiased database of more than 1 million electrocardiogram heart rhythm episodes.